A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
The presence of P+PBac{XP5.WH5}BSC837 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of the progenitor P{XP}d07338 to be Release 3 genomic coordinate 14920996 on chromosome arm 3L. This corresponds to 3L:14965217 and 71A4 on the Release 5 map. The insertion site of the progenitor PBac{WH}FucTAf03774 is Release 5 genomic coordinate 3L:15144157 , which corresponds to 71B6. Consequently, the molecular breakpoints of Df(3L)BSC837 predicted from the Release 5 genomic coordinates of the progenitor transposable element insertion sites are 3L:14965217 ;15144157 and the cytological breakpoints predicted from these coordinates are 71A4;71B6.